{"generic":"Catumaxomab","drugs":["Catumaxomab"],"mono":{"0":{"id":"jxuos0","title":"Generic Names","mono":"Catumaxomab"},"1":{"id":"jxuos1","title":"Dosing and Indications","sub":{"0":{"id":"jxuos1b4","title":"Adult Dosing","mono":"<ul><li>catumaxomab has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li><b>Malignant ascites, EpCAM-positive, when standard therapy not available or feasible:<\/b> 10 mcg on day 0, 20 mcg on day 3, 50 mcg on day 7, and 150 mcg on day 10 infused INTRAPERITONEALLY over at least 3 hours; at least 2 days must elapse before the next infusion, and the infusion interval may be prolonged based on tolerability; overall treatment period should be no greater than 20 days; premedicate with analgesic, antipyretic, or NSAID (European Medicines Agency-approved dosing)<\/li><\/ul>"},"1":{"id":"jxuos1b5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients younger than 18 years "},"3":{"id":"jxuos1b7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Malignant ascites, EpCAM-positive, when standard therapy not available or feasible<br\/>"}}},"3":{"id":"jxuos3","title":"Contraindications\/Warnings","sub":[{"id":"jxuos3b9","title":"Contraindications","mono":"<ul><li>hypersensitivity to catumaxomab or any component of the product<\/li><li>hypersensitivity to murine (rat or mouse) proteins<\/li><\/ul>"},{"id":"jxuos3b10","title":"Precautions","mono":"<ul><li>cytokine release-related symptoms (eg, dyspnea, fever, vomiting, and hypo- or hypertension) have been reported; premedication recommended<\/li><li>hemodynamic insufficiency, edema, hypovolemia, hypotension, acute renal impairment, or hypoproteinemia; assess and resolve prior to each infusion<\/li><li>hepatic impairment (severe), liver metastases greater than 70%, portal vein thrombosis or obstruction<\/li><li>infections, acute, or other factors interfering with the immune system; use not recommended<\/li><li>performance status, solid, defined as BMI greater than 17 (after fluid drainage) and Karnofsky Index greater than 60; required before administration<\/li><li>renal impairment, moderate or severe<\/li><li>systemic inflammatory response syndrome (ie, fever, tachycardia, tachypnea, and leukocytosis), often within 24 hours of infusion, has been reported; standard therapy or premedication recommended<\/li><\/ul>"},{"id":"jxuos3b11","title":"Pregnancy Category","mono":"Unknown<br\/>"},{"id":"jxuos3b12","title":"Breast Feeding","mono":"Unknown<br\/>"}]},"5":{"id":"jxuos5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Abdominal pain (43.7%), Diarrhea (10% or greater), Nausea (10% or greater), Vomiting (10% or greater)<\/li><li><b>Other:<\/b>Fatigue (10% or greater), Fever (10% or greater), Shivering (10% or greater)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Erythema induratum (0.1% to less than 1%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage (0.1% to less than 1%)<\/li><li><b>Hematologic:<\/b>Thrombocytopenia (0.1% to less than 1%)<\/li><li><b>Immunologic:<\/b>Systemic inflammatory response syndrome (3.8%)<\/li><li><b>Renal:<\/b>Acute renal failure (0.1% to less than 1%)<\/li><li><b>Respiratory:<\/b>Pleural effusion (1% to less than 10%), Pulmonary embolism (0.1% to less than 1%)<\/li><\/ul>"},"6":{"id":"jxuos6","title":"Drug Name Info","sub":{"2":{"id":"jxuos6b19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>Monoclonal Antibody<\/li><\/ul>"},"3":{"id":"jxuos6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"9":{"id":"jxuos9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>intraperitoneal use only; do not administer as a bolus or by another route<br\/><\/li><li><b>Intraperitoneal<\/b><br\/><ul><li>dilute and administer only with specific polypropylene syringes, polyethylene perfusion tubing, polycarbonate infusion valves, and polyurethane solution-coated catheters<\/li><li>drain ascites fluid via catheter until flow stops or symptom relief prior to each dose; infuse 500 mL sodium chloride prior to each dose to support antibody distribution<\/li><li>withdraw appropriate amount of NS with 50-mL syringe (air buffer of at least 3 mL will be left in syringe); insert catumaxomab prefilled syringe cannula through the 50-mL syringe and inject directly into NS reservoir; do not draw back plunger rod to rinse prefilled syringe; place cap on 50-mL syringe and shake gently<\/li><li>insert 50-mL syringe into the constant infusion pump system and infuse at a constant rate over at least 3 hours; consider a 6-hour infusion for the first dose, depending on patient health status<\/li><li>administer prepared solution immediately if possible; may be stored for up to 48 hours at 2 to 8 degrees C or 24 hours at 25 degrees C or less<\/li><li>leave intraperitoneal catheter in abdominal cavity for entire treatment period<\/li><\/ul><\/li><\/ul>"}}}